Unum Therapeutics has listed on the Nasdaq Global Select Market, providing exits to Novo, Sanofi, EMS and Seattle Genetics.

KU Leuven returned for the automated DNA diagnostic spinout's series A round, which follows a $2.3m round in 2016 and $1.5m raised in 2015.

Novartis-backed Homology Medicines priced its shares at $16 and raised $165m when it floated on the Nasdaq Global Select Market.

Abbott has contributed to the $18m second tranche of diabetes management technology developer Bigfoot Biomedical's latest round.

Proceeds from the round, which included Lilly Asia Ventures, will be used to advance Tempest Therapeutics' lead enzyme inhibitor into the clinic.

Novo Ventures, an investor in the biological research tool producer since its series A round, returned for a series D that took its total funding to $86m.

The pharmaceutical company injected more than $2bn into life science businesses in 2017 and recorded 14 exits.

Symbiotix has licensed more Harvard IP to propel the commercialisation of T-cell modulators based on studies of the human microbiome.